Antroquinonol
Sponsors
Golden Biotechnology Corporation
Conditions
Atopic DermatitisCovid-19HBVHyperlipidemiasLeukemia, Myeloid, AcuteNon-small Cell Lung CancerNon-small Cell Lung Cancer Stage IVPancreatic Neoplasm
Phase 1
Determine MTD and to Evaluate pk, Safety/Tolerability and Efficacy Profiles of Hocena® in NSCLC Subjects
CompletedNCT01134016
Start: 2010-12-31End: 2013-06-30Updated: 2016-06-21
Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer
CompletedNCT03310632
Start: 2017-12-01End: 2024-01-02Updated: 2026-07-02
Phase 2
Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC
CompletedNCT02047344
Start: 2013-10-31End: 2018-12-07Updated: 2019-12-26
Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia
CompletedNCT02719028
Start: 2016-05-31End: 2019-03-31Updated: 2020-01-02
A Trial of Antroquinonol in Patients With Atopic Dermatitis
CompletedNCT03622463
Start: 2018-07-17End: 2019-07-09Updated: 2019-08-29
A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B
CompletedNCT03625102
Start: 2018-08-01End: 2023-06-16Updated: 2023-09-13
Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients
CompletedNCT03823352
Start: 2019-02-20End: 2020-12-31Updated: 2021-02-03
Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients
CompletedNCT04523181
Start: 2020-10-15End: 2021-12-23Updated: 2023-12-13